Pharmacokinetics and Pharmacodynamics of LMP400

Antony S, Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. Pommier Y, The indenoisoquinoline nonCamptothecin topoisomerase I inhibitors: update and perspectives. Read more

Candeil L. ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastases. Stenvang J. Targeting the topoisomerase I enzyme in cancer cells with acquired resistance to SN-38. Jensen NF. Characterization of DNARead more

Burton JH. NCI Comparative Oncology Program Testing of Non-Camptothecin Indnoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.Read more

Kummar S. Clinical and pharmacologic evaluation of two dosing schedules of indenothecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.Read more

Tang SW. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.Read more

Murai J. SLFN11 Blocks Stress Replication Forks Independently of ATR. Pommier Y. Indotecan (LMP400), Imidotecan (LMP776) and LMP744: a new class of non-camptothecin TOP1 inhibitors selective for cancer cells with homologous recombination deficiencies and highRead more

Aris S. Potentiation of the novel Topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor, AZD7762.Read more